News | April 20, 2012

Cervical Scan to Reduce Post-Pap Biopsies Unveiled at British Medical Conference

April 20, 2012 — Guided Therapeutics Inc. announced this week that the LuViva Advanced Cervical Scan is being introduced to medical leaders at the 40th Anniversary Meeting of the British Society for Colposcopy and Cervical Pathology (BSCCP) in Gateshead, United Kingdom, by Eurosurgical Ltd., the company’s U.K. distributor. The meeting runs April 18-20.

In the U.K., LuViva is initially intended as a follow-up test after a positive Pap test. Today in the U.K., approximately 400,000 women annually are referred to more than 170 institutions for a follow-up or colposcopy examination, which often involves a biopsy of the cervix. Based on its clinical trial results, LuViva could eliminate approximately 40 percent of unnecessary follow-up procedures and could identify serious cervical disease up to two years earlier than the standard of care.

“The BSCCP meeting is an important gathering of leading women’s healthcare providers from across the U.K. and Ireland and an excellent venue to introduce LuViva ahead of its anticipated launch later this year,” said Mark L. Faupel, Ph.D., CEO and president of Guided Therapeutics Inc.

Eurosurgical purchased, and recently received, the first LuViva demonstration unit shipped to the European Union. Demonstration units are designed to educate the sales force and show the functionality of the product to medical professionals. The company anticipates CE mark approval in the second quarter of 2012.

“Eurosurgical is pleased to be at the forefront of improving women’s healthcare through new and innovative technologies like LuViva,” said Peter Parker, managing director of Eurosurgical Ltd.

LuViva is a diagnostic device that scans the cervix with light and uses spectroscopy to measure how light interacts with the cervical tissue. Spectroscopy identifies chemical and structural indicators of pre-cancerous cells that may be below the surface of the cervix or misdiagnosed as benign. This technique is called biophotonics. Unlike Pap, HPV tests or biopsies, LuViva does not require laboratory analysis or a tissue sample, and is designed to provide results immediately, which eliminates costly, painful and unnecessary testing. LuViva is designed for use with women who have undergone initial screening and are called back for follow-up with a colposcopy examination, which in many cases involves taking a biopsy of the cervix. The device is used in conjunction with the LuViva Cervical Guide single-use patient interface and calibration disposable.

The Guided Therapeutics LuViva Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use.

For more information: www.eurosurgical.co.uk, www.guidedinc.com

Related Content

Study Examines Characteristics of Mobile Mammography Patients
News | Mammography | October 18, 2017
Significant differences were found among women receiving mammography at a cancer center versus those visiting a mobile...
Machine Learning Identifies Breast Lesions Likely to Become Cancer
News | Artificial Intelligence | October 18, 2017
A machine learning tool can help identify which high-risk breast lesions are likely to become cancerous, according to a...
Volpara Solutions to Showcase VolparaEnterprise Live! at RSNA
News | Mammography | October 16, 2017
Volpara Solutions will introduce VolparaEnterprise Live!, a mammography quality control tool, at the 2016 Radiological...
TMIST Mammography Study Opens Enrollment
News | Mammography | October 16, 2017
The Tomosynthesis Mammographic Imaging Screening Trial (TMIST), the first randomized trial to compare two types of...
Sponsored Content | Whitepapers | Imaging | October 13, 2017
As we strive to increase value and decrease cost of health delivery, clinical collaboration and efficiency become key...
FDA Clears Siemens Magnetom Terra 7T MRI Device

FDA Clears Siemens Magnetom Terra 7T MRI Device

Technology | Magnetic Resonance Imaging (MRI) | October 12, 2017
The U.S. Food and Drug Administration (FDA) cleared the first 7 Tesla (7T) magnetic resonance imaging (MRI) device,...
National Breast Center Founder Names Top Three Innovations in Breast Cancer Treatment
News | Women's Health | October 11, 2017
In 2017, invasive breast cancer will be diagnosed in about 252,710 women and 2,470 men in the U.S. and remains the...
ACR Appropriateness Criteria Add Topics, Increase Diagnostic Imaging Clinical Scenarios
News | Clinical Decision Support | October 11, 2017
October 11, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the...
News | Brachytherapy Systems | October 05, 2017
External researchers presented new clinical data supporting the use of iCAD’s Xoft Axxent Electronic Brachytherapy (eBx...
Joint Venture Partnership Opening 16 New Breast Screening Sites in Texas
News | Breast Imaging | October 04, 2017
HCA Healthcare Gulf Coast Division and Solis Mammography have entered into a joint venture agreement to make breast...
Overlay Init